Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in

Trial Profile

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX-3379 (Primary) ; Vemurafenib (Primary)
  • Indications Carcinoma; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals

Most Recent Events

  • 03 Apr 2017 Status changed from active, no longer recruiting to completed.
  • 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
  • 26 Feb 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top